Companies: 10,795·Total market cap: $144.5T
Orion Biotech Opportunities Corp.

Orion Biotech Opportunities Corp.

ORIANASDAQFinancial Services
$10.23
+$0.00(+0.00%)
Market Cap$0
P/E Ratio—
52W High$12.0
52W Low$9.71
PE RatioMarket CapForecast

Orion Biotech Opportunities Corp. (ORIA) PE Ratio — Current & Historical Data

Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.

oria · pe ratio · data through Dec 31, 2022

Core PE Ratio Metrics

Trailing 12 months · TTM

The price-to-earnings (P/E) ratio for Orion Biotech Opportunities Corp. (ORIA) measures how much investors pay for each dollar of the company's trailing earnings. ORIA's current PE ratio of 11.11x is calculated by dividing its stock price of $10.23 by its TTM earnings per share of $0.92. +1.8% elevated vs 5Y avg 10.9x

11.11x
P/E Ratio (TTM)+1.8%

Source: FMP · /ratios-ttm · /analyst-estimates · 2022-12-31

Forward P/E
N/A
—
EPS (TTM)
$0.92
TTM · diluted EPS
PEG Ratio
0.00
Below 1.0 · Growth adjusted
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Orion Biotech Opportunities Corp. SEC 10-K & 10-Q filings · US GAAPUpdated: 2026-06-09

PE Ratio History

2021 – 2022 · Annual
PE Ratio (TTM)
5Y Avg 10.9x
EPS (Annual)

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)

PE Ratio vs Peers

Shell Companies · 6 peers · Annual PE
CompanyMarket CapPE (Annual)vs AvgEPS (TTM)
Orion Biotech Opportunities Corp.
Orion Biotech Opportunities Corp.You
ORIA
—11.11x-84.4%$0.92
Alpha Partners Technology Merger Corp.
Alpha Partners Technology Merger Corp.
APTM
$243MN/A—-$31.14
Build Acquisition Corp.
Build Acquisition Corp.
BGSX
$255MN/A—-$0.04
Corazon Capital V838 Monoceros Corp
Corazon Capital V838 Monoceros Corp
CRZN
$260MN/A—-$0.05
Frontier Acquisition Corp.
Frontier Acquisition Corp.
FRON
$299M134.46x+89.0%$0.07
Green Visor Financial Technology Acquisition Corp. I
Green Visor Financial Technology Acquisition Corp. I
GVCI
$265M7.85x-89.0%$1.32
TB S.A. Acquisition Corp
TB S.A. Acquisition Corp
TBSA
$255MN/A——
Industry Average
2 peers with valid PE
—71.16xbaseline—

* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio

Annual PE Ratio History

Showing 2 of 2 years
Fiscal Year EndPE RatioEPS (TTM)YoY ChangePE vs Max
2022-12-31Latest
FY2022
10.92x$0.92—
2021-12-31
FY2021
—$-0.04—

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API

About PE Ratio & Methodology

The price-to-earnings (P/E) ratio for Orion Biotech Opportunities Corp. (ORIA) measures how much investors pay for each dollar of the company's trailing earnings. ORIA's current PE ratio of 11.11x is calculated by dividing its stock price of $10.23 by its TTM earnings per share of $0.92.

PE Ratio = Stock Price ÷ EPS (TTM)
= $10.23 ÷ $0.92 = 11.11x
TTMTrailing Twelve Months — sum of the most recent 4 quarterly EPS figures
Forward PEStock price ÷ analyst consensus EPS estimate for the next fiscal year
PEGPE ÷ earnings growth rate — values below 1.0 suggest growth may justify the premium
Figures tie to SEC 10-K/10-Q and FMP ratio endpoints where noted.
Price historyFinancial statementsEarnings

Frequently asked questions

ORIA pe ratio · 6 questions

ORIA's current PE ratio is 11.11x as of 2026-06-09, based on a stock price of $10.23 and TTM EPS of $0.92. Data sourced from Financial Modeling Prep via ORIA's SEC 10-K and 10-Q filings.

ORIA PE ratioWhat is ORIA PE ratioCurrent PE ratio of ORIAORIA PE ratio today

▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Orion Biotech Opportunities Corp. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09